Products Categories
CAS No.: | 21535-47-7 |
---|---|
Name: | Mianserin hydrochloride |
Molecular Structure: | |
Formula: | C18H20N2.HCl |
Molecular Weight: | 300.831 |
Synonyms: | Dibenzo[c,f]pyrazino[1,2-a]azepine,1,2,3,4,10,14b-hexahydro-2-methyl-, monohydrochloride (8CI,9CI);Athymil;Bolvidon;GB 94;Lantanon;Mianserin hydrochloride;NSC 292267;Norval;Org GB 94;Tetramide;Toluon;Tolvin;Tolvon;mianserin HCl; |
EINECS: | 244-426-7 |
Density: | 1.18 g/cm3 |
Melting Point: | >230 °C (dec.) |
Boiling Point: | 411.3 °C at 760 mmHg |
Flash Point: | 186.1 °C |
Solubility: | 3.4 mg/mL in water |
Appearance: | Off-white solid |
Hazard Symbols: | Xn, Xi |
Risk Codes: | 22 |
Safety: | 7-16-36/37-45 |
Transport Information: | UN 3249 |
PSA: | 6.48000 |
LogP: | 3.88880 |
What can I do for you?
Get Best Price
The Bolvidon with the cas number 21535-47-7, is also called (1)1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,f)-pyrazino(1,2-a)azepine monohydrochloride; (2)1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine hydrochloride; (3) Athymil ; (4) Bolvidon ; (5)Dibenzo(c,f)pyrazino(1,2-a)azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-, monohydrochloride; (6) EINECS 244-426-7 ; (7) GB 94 ; (8) Lerivon ; (9) Mianserin HCl ; (10) Mianserin hydrochloride ; (11) Mianserine hydrochloride ; (12) Norval ; (13) ORG GB 94 ; (14) Tolvin ; (15) Tolvon ; (16) UNII-2X03TN217S. It belongs to Serotonin receptor product categories.
Properties of Bolvidon are: (1)ACD/LogP: 3.67 ; (2)# of Rule of 5 Violations: 0 ; (3)ACD/LogD (pH 5.5): 1.66 ; (4)ACD/LogD (pH 7.4): 3.29 ; (5)ACD/BCF (pH 5.5): 3.56 ; (6)ACD/BCF (pH 7.4): 151.22 ; (7)ACD/KOC (pH 5.5): 23.21 ; (8)ACD/KOC (pH 7.4): 986.89 ; (9)#H bond acceptors: 2 ; (10)#H bond donors: 0 ; (11)#Freely Rotating Bonds: 0 ; (12)Polar Surface Area: 6.48 Å2 ; (13)Flash Point: 186.1 °C ; (14)Enthalpy of Vaporization: 66.38 kJ/mol; (15)Boiling Point: 411.3 °C at 760 mmHg ; (16)Vapour Pressure: 5.65E-07 mmHg at 25°C
The Bolvidon appears to be white and film coated tablet, and seem to be white or white-Like after removing it's film coat. It is mainly used for treatment with depression. Bolvidon is well tolerated, especially in elderly patients and patients with cardiovascular disease. During treatment, Bolvidon has no anticholinergic effects, nor obvious cardiovascular system reactions. When you are using Bolvidon, please take the following precautions: firstly, daily amount can be taken divided into several time, but the best meal served in bedtime can take time to improve (night sleep). Seconly, when clinical symptoms has improved, it still should maintain the drug therapy for several months. At last, this medicine is water-soluble, and film-coated tablet, swallowed with a few water, and do not chew.
You can still convert the following datas into molecular structure :
1. SMILES: Cl.c42c(N3C(c1ccccc1C2)CN(C)CC3)cccc4
2. InChI: InChI=1/C18H20N2.ClH/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19;/h2-9,18H,10-13H2,1H3;1H
The Bolvidon toxic data can be showed in the following sheet.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
monkey | LDLo | oral | 200mg/kg (200mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD GASTROINTESTINAL: ULCERATION OR BLEEDING FROM SMALL INTESTINE | Pharmacological and Biochemical Properties of Drug Substances. Vol. 3, Pg. 56, 1981. |
mouse | LD50 | intraperitoneal | 117mg/kg (117mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 14, Pg. 484, 1983. | |
mouse | LD50 | intravenous | 31mg/kg (31mg/kg) | BEHAVIORAL: TREMOR LUNGS, THORAX, OR RESPIRATION: DYSPNEA BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Pharmacological and Biochemical Properties of Drug Substances. Vol. 3, Pg. 56, 1981. |
mouse | LD50 | oral | 224mg/kg (224mg/kg) | SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Sankyo Kenkyusho Nempo. Annual Report of Sankyo Research Laboratories. Vol. 31, Pg. 112, 1979. |
mouse | LD50 | subcutaneous | 118mg/kg (118mg/kg) | SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE SKIN AND APPENDAGES (SKIN): HAIR: OTHER | Sankyo Kenkyusho Nempo. Annual Report of Sankyo Research Laboratories. Vol. 31, Pg. 112, 1979. |
rat | LD50 | intraperitoneal | 262mg/kg (262mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) | Sankyo Kenkyusho Nempo. Annual Report of Sankyo Research Laboratories. Vol. 31, Pg. 112, 1979. |
rat | LD50 | intravenous | 31850ug/kg (31.85mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 14, Pg. 484, 1983. | |
rat | LD50 | oral | 780mg/kg (780mg/kg) | BEHAVIORAL: TREMOR BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Pharmacological and Biochemical Properties of Drug Substances. Vol. 3, Pg. 56, 1981. |
rat | LD50 | subcutaneous | > 3gm/kg (3000mg/kg) | SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Sankyo Kenkyusho Nempo. Annual Report of Sankyo Research Laboratories. Vol. 31, Pg. 112, 1979. |
women | TDLo | oral | 18mg/kg (18mg/kg) | BEHAVIORAL: COMA CARDIAC: PULSE RATE CARDIAC: OTHER CHANGES | Human Toxicology. Vol. 6, Pg. 401, 1987. |
women | TDLo | oral | 28mg/kg/5W (28mg/kg) | BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" CARDIAC: CHANGE IN RATE LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES | British Medical Journal. Vol. 284, Pg. 1912, 1982. |